Amgen Issues Statement on Court of Appeals Ruling That Affirms Preliminary Injunction Against Roche

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Today the United States (U.S.) Court of Appeals for the Federal Circuit issued a ruling that affirms the preliminary injunction ordered by the U.S. District Court in Boston barring Roche from selling its pegylated-erythropoietin (peg-EPO) product MIRCERA in the U.S.

Amgen (NASDAQ:AMGN) issued the following statement regarding today's ruling by the Court of Appeals:

Amgen is pleased that the Court of Appeals has affirmed the preliminary injunction barring Roche from selling its peg-EPO product in the U.S. in violation of Amgen's erythropoietin (EPO) patents. Last week, the District Court ruled that Amgen is entitled to a permanent injunction and upheld the prior jury verdict and court rulings regarding the infringement, validity and enforceability of 10 claims of four of Amgen's patents.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit

Source: Amgen

Emma Hurley (805) 447-7845 (media)
Arvind Sood (805) 447-1060 (investors)